We would love to hear your thoughts about our site and services, please take our survey here.
Once a week, Pigster? Closed Boarders! 6 weeks and then no more Covid. No entry without a negative test result. Sorted.
Not so easy when you have 50 to 100 million population though.
The big question is how many LFD can Abingdon and BBI make per week once production is ramped up and how many other partnerships can Avacta get in place? I spy two or three potentials on my radar!
Exciting times to sort this situation!
Cheers, Rich
Oh yes, Mr Alastair Smith (soon to be Sir) and the Rt Honourable Member of Parliament and Prime Minister Mr Boris Johnson.
When it does I think you will fid our share price will absolutely fly to the Moon!
Set your target price for circa £8 to £12.
First shipments in October from BBI ;-)
Well lets hope so!
A good step up today! Thanks to Hardy AIM and a few other buyers! I had a cheeky £10K into the close!
Cheers and all the best, Rich
However the Avacta share chat board is loading its way!
Please folks keep on point!
The importance of our LFD is beyond doubt! It’s impact when it arrives will be off the scale.
I have no doubt it is coming and BBI and Abingdon are going to be scaling up production and we are more than likely to see more than one additional production partnerships sooner rather than later.
AVA6000 targeted chemotherapy treatment from Stage 1 clinical trials is coming soon.
The need for in body testing of a virus blocker has just increased in significance and give the current failure to get a vaccine to first stage by others a blocker would be a huge step.
Let’s see some focus.
Cheers Rich
Jimmy, it underlines the massive need for super fast, accurate testing. But, we must have a fully validated test which is dependable that nobody can talk it down, then it will be the gold standard!
But, every investor and person in the country would like to see our test in use tomorrow and available to all, every day as needed. It can and will transform every day life during the current mess!
Add in a Covid19 virus blocker and we have the complete package. We need to stop the virus before it takes hold!
Looking forward to the Alistair Smith major press release!
Cheers Rich
Here is a question?
Answer around £700.
How big is the market?
How many labs around the world want to be able to diagnose changes in the virus, every single one!
Market? Huge!
What is important? specivity!
Who has the best?
Avacta!
A few thoughts.
Cheers, Rich
Just to be clear, from my side. I totally expect the valuation of the business based on not only successful sales of the fastest and most simple Covid19 test in the world which will initially give not only the accuracy needed to give POC testing the safest indication outside a lab of Covid19 presence will be determined by UK, EU and Global sales. The production capacity will determine what can be sold and I expect sales to exceed production for months ahead. In this case we can be sure to expect sales in excess of 5 million per week and growing as the world realises how effective this test is and how simple. If we have sufficient manufacturing capacity from BBI and Abingdon to meet UK demand, but we will surely need manufacturing partners in Europe, Asia, the US and South America. Global sales may well run into billions per month. If Avacta can ensure they can liberate profits of £1 billion per year which is more than possible from sales then a market cap of 2 to 3 billion is not off reality given all the other developments. So £8 to £12 is a good target to have for early 2021. Sure it could be way higher than this or lower depending on other developments in the world.
One point to note, if Avacta to manage to pursue a joint listing especially on the NASDAQ which will definitely require a move in to the FTSE, with advances on other projects the value could increase dramatically beyond my above pointers.
There are lots of if's and but's. But no-one can really give a proper valuation. Note even the brokers have clear valuation at this point.
But I am looking for £8 as my current target. £20 remains a strong possibility with successful AVA6000 clinical trials.
I'll leave you to discuss!
Cheers, Rich
Well I invested in this company when the share price was in the 30’s pence. This was in April. Today the share price only 5 months later is £1.7x.
In 6 months time it is likely to be well over £5 per share or possibly much higher. Can someone please explain why people are not very excited indeed. The returns and opportunities get better and better.
Cheers Rich
https://mailchi.mp/turnerpope.com/avactagroupplc07092020?e=12f2b2cf63
Turner Pope update the status following todays RNS.
Cheers, Rich
This might not be a week for trading. It might be a week for buying.
The company clearly will be releasing news of multiple brands covering a range of diagnostic tools for Covid19 and others under the AffiDX brand which will revolutionise testing across the spectrum. But, the POC LFD is looking like it really will be the UK biggest step change giving mass testing. With ramped up production coming that will be serious income.
Add in BAMS and late 2020 early 21 Phase 1 clinical trials of AVA6000 people’s investment here are likely to be worth considerably more than today.
This month could be very good indeed!
Have a great week all!
Cheers Rich
RedReversion, this is all under the new trade mark registered in the 6th August AffiDX.
This is available in the public domain, but will likely to be made public in a very likely RNS introducing the full range of diagnostic tests using Affimer’s from Avacta.
In the meantime we need these tests in place, before we have people being seriously ill and dying from all the other illnesses which have effected people for years, which are not getting the required treatment and care. People are living in fear and we need normality. These tests will enable us the affordable a sense of normality.
Let’s hope BBI and Abingdon Health as well as any other LFD manufactures can get in board as soon as possible. However million of devices will take time to produce.
The time is now here to get our products out there. Of course being fully validated and perfected.
Cheers Rich
@11:41 PL75, interesting proposition that the Avacta POC LFD test if chosen as a major supplier, which it absolutely should. No other test will be able to be used giving results in less than ten minutes without medical supervision! I think the tests will be sold under the trade name AffiDX. Watch this space!
The value of Avacta is about to rise significantly.
Investors better get ready.
Cheers Rich
Not sure about that @ StarJump, as it was easy to pick up shares today. No quantity I tried gave me NT.
Cheers, Rich
Basscadet, you have to be on SETS. AIM companies unless they are in the AIM50 are on SETqx and use a market maker, for electronic trading when dual listed the company needs to be on SETS. so if 4d Pharma for a NASDAQ listing they would need to move to the FTSE. This would be a huge advantage to investors and the market. Expect to see a significant rise in SP when that happens especially combined with big positive results.
You can find some explanation of the exchanges here - https://www.londonstockexchange.com/trade/equity-trading.
@noix - thanks for the pointers there and the welcome!
Cheers, Rich
The one at 15:56 is more relevant as that is going to be a PI with some available funds building a stake here.
Cheers, Rich
This interview with Duncan Peyton gives a real insight to the current situation and there is a strong hint of looking for more investors from the US. If they wanted to list in the US they would need to move off AIM. A dual listing on a US exchange would bring a lot of new investors. But, if these trials are successful it is worth noting that Merck & Co would be a very strong candidate to buy this company and they would have the means to give a strong valuation on what they believe the company would be valued at!
https://youtu.be/gDJVJcIDZAM - with a watch, for any new comers - like me...
Cheers, Rich
You do have to wonder why, as a broker, Turner Pope are unable to give guidance on a target market valuation for Avacta?
£2.00 / £4.00 / £10.00 / £20.00 - there is of course no doubt we are working in a fluid market, but as the broker they should be able to get an insight into Avacta's target sales and revenue to give some guidance based on sales of a certain number of tests? Lets face it nearly every broker target is wrong, but hey have a stab Turner Pope give the investors something to get excited about!!
Maybe we will get the mother of RNS's tomorrow on the LFD and we can get another super exciting interview on Directors Talk, hopefully it will include Mr Alastair Smith not letting poor Giles getting a word in edgeways as he has so much to say they run out of time and Giles , just manages to get in - "Many thanks for your time Alistair"
Even better we have solid interviews on the BBC and Sky news and everyone in the UK buys shares in Avacta!
Then the share price will rise a touch...
Have a great evening all!
Cheers, Rich
PS - Thanks for the acknowledgment PL75 - nice touch.
PPS - Whoever asked Admin to remove Ophidian's post from last night really needs to get over themselves. There was a clear message the readers of this board appreciate his input and experience based on the number of people who recomended it and made positive comments there after. The amount of total rubbish posted on here some days just wastes everyone's time. Quality is always better than quantity!
I see my friend Ophidian has checked in here! That is good news! It is good to have someone with top 'pharma project management skills' giving comment!
If I was going to stalk another investor with great research knowledge on LSE it would be Ophidian, BigByteNow and a just a handful of others!
In the meantime the right news releases here will see a very good return for investors. Success and implementation of tumour reduction or even better elimination on these cancers would be a huge breakthrough. Treatments on Parkinson's would be a huge step too.
These investments can make very good returns indeed on success and it looks very strong from initial results!
Cheers, Rich